Industry news that matters to you.  Learn more

Quest Diagnostics to Acquire Celera

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world’s pioneers in genetic diagnostics discovery and development, announced last week that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.

23andMe Receives NIH Funding to Evaluate Web-Based Research on the Genetics of Drug Response

Genetic testing company 23andMe announced last week the launch of a project that aims to use web surveys to improve personalized medicine. The project, supported by the National Institutes of Health (NIH), plans to validate 23andMe’s highly-scalable platform for pharmacogenomics research. The company received $190,000 in stimulus funding from the American Recovery and Reinvestment Act of 2009 for “Web-based Phenotyping for Genome-Wide Association Studies of Drug Response” from NIH’s National Human Genome Research Institute (NHGRI).